Literature DB >> 6370573

Comparative study of the ability of four aminoglycoside assay techniques to detect the inactivation of aminoglycosides by beta-lactam antibiotics.

M A Pfaller, G G Granich, R Valdes, P R Murray.   

Abstract

In vitro inactivation of aminoglycosides (tobramycin, gentamicin, and amikacin) by beta-lactams (cefazolin, cefotaxime, moxalactam, carbenicillin, piperacillin, mezlocillin, and azlocillin) was measured using the enzyme-mediated immunoassay (EMIT), fluorescence polarization immunoassay ( TDX ), radioimmunoassay (RIA), and bioassay. No significant inactivation of aminoglycosides was produced by high levels of the three cephalosporins as measured by EMIT, RIA, or bioassay. Inactivation of tobramycin and gentamicin by mezlocillin and azlocillin was comparable to that seen with piperacillin but less than that with carbenicillin. In general, the bioassay detected the greatest degree of aminoglycoside inactivation and the EMIT assay detected the least for all drug combinations. The TDX and RIA techniques were equivalent in their ability to detect aminoglycoside inactivation by beta-lactam antibiotics.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6370573     DOI: 10.1016/0732-8893(84)90003-8

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  3 in total

1.  In vitro inactivation of aminoglycosides by sulbactam, other beta-lactams, and sulbactam-beta-lactam combinations.

Authors:  P C Fuchs; S Stickel; P H Anderson; A L Barry; S Shilling
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

2.  In vitro inactivation of aminoglycosides by apalcillin.

Authors:  D N Wright; D C Hale; B Saxon; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

3.  An in vivo assessment of the tobramycin/ticarcillin interaction in cystic fibrosis patients.

Authors:  G W Roberts; R L Nation; A O Jarvinen; A J Martin
Journal:  Br J Clin Pharmacol       Date:  1993-10       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.